Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication.
about
Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expressionHerpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5ICP0 prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cellsFormation of nuclear foci of the herpes simplex virus type 1 regulatory protein ICP4 at early times of infection: localization, dynamics, recruitment of ICP27, and evidence for the de novo induction of ND10-like complexesThe herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genesThe genome of canarypox virusFunctional inaccessibility of quiescent herpes simplex virus genomesThe potential link between PML NBs and ICP0 in regulating lytic and latent infection of HSV-1Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNAThe ORF45 protein of Kaposi's sarcoma-associated herpesvirus is associated with purified virions.Herpes simplex type I (HSV-1) infection of the nervous system: is an immune response a good thing?Comparison of the biological and biochemical activities of several members of the alphaherpesvirus ICP0 family of proteins.Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activityA herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigsInterferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1Herpes simplex virus-1 induces expression of a novel MxA isoform that enhances viral replication.Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy.Interferon regulatory factor 3-dependent pathways are critical for control of herpes simplex virus type 1 central nervous system infection.Beta interferon and gamma interferon synergize to block viral DNA and virion synthesis in herpes simplex virus-infected cells.Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1.hTERT extends the life of human fibroblasts without compromising type I interferon signaling.Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo.Strain-dependent structural variants of herpes simplex virus type 1 ICP34.5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potentialICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency.Characterization of a potent refractory state and persistence of herpes simplex virus 1 in cell culture.Herpes simplex virus type 1 and bovine herpesvirus 1 latency.Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in miceHandling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses.Herpes simplex virus type 2 virion host shutoff protein regulates alpha/beta interferon but not adaptive immune responses during primary infection in vivo.HSV-2 inhibits type-I interferon signaling via multiple complementary and compensatory STAT2-associated mechanismsHuman cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells.Viruses with deletions in antiapoptotic genes as potential oncolytic agents.Selective ablation of virion host shutoff protein RNase activity attenuates herpes simplex virus 2 in mice.Towards an effective genital herpes vaccine: past lessons and future prospects.The zinc RING finger of bovine herpesvirus 1-encoded bICP0 protein is crucial for viral replication and virulence.Delivery of Interferon-gamma by an adenovirus vector blocks herpes simplex virus Type 1 reactivation in vitro and in vivo independent of RNase L and double-stranded RNA-dependent protein kinase pathways.Differential functions of interferon-upregulated Sp100 isoforms: herpes simplex virus type 1 promoter-based immediate-early gene suppression and PML protection from ICP0-mediated degradationHerpes simplex virus 1 ubiquitin-specific protease UL36 inhibits beta interferon production by deubiquitinating TRAF3.Herpes simplex virus 1 serine/threonine kinase US3 hyperphosphorylates IRF3 and inhibits beta interferon production.Two overlapping regions within the N-terminal half of the herpes simplex virus 1 E3 ubiquitin ligase ICP0 facilitate the degradation and dissociation of PML and dissociation of Sp100 from ND10.
P2860
Q24298241-A0372301-481C-4142-9A60-F1C17F3FF65DQ24304261-0A03BA6F-FD69-4A45-B4F1-F28B60C40D5EQ24535541-D548C6C5-19CF-47A6-9417-062BEF564467Q24607261-B4CD98B6-A62A-468D-8901-BC63ACC4A2BEQ24607496-EFCDFF4A-5CFF-448F-B412-06AA38812E59Q24630284-60A6B80A-91FF-4799-B020-F744AB6C75F4Q24815909-36D929B5-F803-4E7A-B515-9021CF9F3435Q27027918-7C65EC0B-6717-447E-9444-8297BCA8BD4EQ28118718-C2E810AB-30E6-473F-A0A6-04F58115C8B0Q30453077-0EF09444-D919-4990-80EA-3B74757328A2Q33716707-76DF4D11-F615-4CED-8EEB-736352483A59Q33725595-67BFB92E-9B19-4DC0-84B4-6C6D0E08B034Q33743847-45435304-6EAB-4121-B742-A01C486644FCQ33825931-1916898D-E1F4-4C8E-AA1B-B0D224D21E61Q33908810-760E1505-4F2B-4196-B9AE-DBAAEED6B5CDQ33922329-4EE7644B-873B-45A2-8EA1-03BB6EEEE8AFQ34046125-EA40D57C-47C2-4F64-A4BC-BE021EFAC64CQ34120729-A5166EB2-435A-46E1-AD00-1C8C9A4CFC9DQ34350245-AA74BF83-0CAD-4173-B68D-5A196BA778B5Q34356255-01A10E40-10DF-49EA-9B7C-39E35AB3B7E5Q34614831-715B74F9-A31B-494E-A2C6-D8AA8094F498Q34648184-2674AFE4-2100-472C-800B-E6C4A32544F1Q34744709-174CABC8-8BFB-4D0B-B923-5A583AB2C046Q35013167-057149D3-D4EF-40B2-BB91-76CDE1666BE3Q35024336-674D71EB-A0DE-4CC3-B341-9343F5E4D764Q35044114-21FEFB12-A8DF-4A8F-93D6-B95C44DF7A9EQ35076638-AB114B42-1F3A-45E0-8A01-4B5694AA8F6DQ35161325-1EC6231D-A107-4531-A6C5-7C12B71AE9F4Q35803282-5FCEEAF0-0705-4F7D-B059-56A4744C4206Q36098919-EF9B7B75-7785-491F-98AF-33CBA01A1526Q36161015-84105620-2F54-4A77-9D86-78B9191FB591Q36254857-DE39E65F-45F4-46F0-81F7-AB65558F1A8DQ36498155-FBEBF58E-B128-431D-88E0-266F6077AA71Q36991575-9E1D05C8-4C43-4F24-94E4-E84D65DC9C63Q36994602-D07A7432-6B36-448B-BA94-477BF16C8DC2Q37061759-18316442-B75C-4191-B8A2-F917C904AE58Q37192189-F066AAF3-8FF7-4DBC-85A9-091F2427F4CBQ37252761-6C1E90F4-2184-4491-AEA9-62A777F0E025Q37336521-88DA5062-737D-450C-9DA7-8977B7F923A9Q37336832-A66D50DD-AB98-4FAF-B2B7-5B2586585AE6
P2860
Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Herpes simplex virus ICP0 and ...... barriers to virus replication.
@en
Herpes simplex virus ICP0 and ...... barriers to virus replication.
@nl
type
label
Herpes simplex virus ICP0 and ...... barriers to virus replication.
@en
Herpes simplex virus ICP0 and ...... barriers to virus replication.
@nl
prefLabel
Herpes simplex virus ICP0 and ...... barriers to virus replication.
@en
Herpes simplex virus ICP0 and ...... barriers to virus replication.
@nl
P2860
P1433
P1476
Herpes simplex virus ICP0 and ...... barriers to virus replication.
@en
P2093
James R Smiley
P2860
P304
P356
10.1128/JVI.76.4.1995-1998.2002
P407
P577
2002-02-01T00:00:00Z